Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
individuals. JAIDS. 2019;82:314 320. 2. Hyle EP, Scott JA, Sax PE, et al. Clinical impact and cost effectiveness of genotype testing at HIV diagnosis in the United States. Clin Infect Dis. 2019 [epub ahead of print] 3. Nakagawa F, Miners A, Smith CJ, et al. Projected lifetime healthcare costs associated with HIV infection. PLoS One. 2015;10:e0125018. 4. Krentz HB, Ko K, Beckthold B, et al. The cost of antiretroviral drug resistance in HIV positive patients. Antivir Ther. 2014;19:341 348. 5. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158:84 92. 6. Castro H, Pillay D, Sabin C, et al; Resistance UKCGoHD. Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV 1 drug resistance. BMC Med Res Methodol. 2012;12:30. 7. Cento V, Perno CF. Two drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV 1 treatment naive, virologicallysuppressed patients: latest evidences from the literature on their efficacy and safety. J Glob Antimicrob Resist. 2019. doi: 10.1016/ j.jgar.2019.08.010. 8. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral naive adults with HIV 1 infection (GEMINI 1 and GEMINI2) week 48 results from two multicentre, double blind, randomised, non inferiority, phase 3 trials. Lancet. 2019;393:143 155. 9. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV infected newborns. J Acquir Immune Defic Syndr. 2003;32:292 297. 10. Delaugerre C, Chaix ML, Blanche S, et al. Perinatal acquisition of drug resistant HIV 1 infection: mechanisms and long term outcome. Retrovirology. 2009;6:85. 11. Jochimsen EM. Failures of zidovudine postexposure prophylaxis. Am J Med. 1997;102: 52 55; discussion 56 57. 12. Streeck H, Verheyen J, Storim J, et al. Preexposure prophylaxis failure with tenofovir disoproxil. AIDS. 2017;31:176 177. 13. Dimitrov DT, Boily MC, Hallett TB, et al. How much do we know about drug resistance due to PrEP use? Analysis of experts' opinion and its influence on the projected public health impact. PLoS One. 2016;11:e0158620. 14. Luft LM, Beckthold B, Gill MJ. Increasing HIV subtype diversity in Canadian born patients living in Southern Alberta, Canada. J Acquir Immune Defic Syndr. 2011;57: e27 e29. 15. Panichsillapakit T, Smith DM, Wertheim JO, et al. Prevalence of transmitted HIV drug resistance among recently infected persons in san diego, CA 1996 2013. J Acquir Immune Defic Syndr. 2016;71:228 236. 16. Poon AF, Gustafson R, Daly P, et al. Near real time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study. Lancet HIV. 2016;3:e231 e238. Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
Journal of acquired immune deficiency syndromes